Abstract
Lack of expression of the tumor suppressor CDX2 is associated with stage II/III colorectal cancer (CRC) poor outcomes. Its potential prognostic and predictive values in metastatic CRC (mCRC), and correlation with other potential biomarkers are of great interest. Overexpression of the PTGS2 gene encoding cyclooxygenase 2 (COX2) has shown a significantly direct association with advanced CRC stages. Reduced CDX2 in CRC has been suggested to enhance NF-κB-mediated inflammatory response, upregulating COX2 expression.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
